About this trial
This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.
Eligibility criteria
Qualifiers
English-speaking, literate adults,
Male or female,
Between the ages of 18-55,
Body Mass Index from 18.5-32.0 kg/m2,
Disqualifiers
Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),
Current or past history of major psychiatric disorder that would limit ability to participate in the study,
Use of cannabis exclusively for medical reasons (no recreational use reported),
Trial design
Treatments tested in this trial
- Cannabidiol, Medium Dose
- Cannabidiol, Higher Dose
- Active Inhaled Cannabis
- Placebo Cannabidiol
- Placebo Inhaled Cannabis
Treatment groups
6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Hannah Harris
Lead sponsor
University of Kentucky
Sponsor institution
National Institute on Drug Abuse (NIDA)
Collaborator